Related Articles Survival after non-resection of colorectal cancer: the argument for including non-operatives in consultant outcome reporting in the UK. Ann R Coll Surg Engl. 2019 Feb;101(2):126-132 Authors: Abdel-Halim M, Wu H, Poustie M, Beveridge A, Scott N, Mitchell PJ Abstract INTRODUCTION: Although the mainstay of colorectal cancer treatment remains operative, a significant proportion of patients end up without surgery. This is because they are either deemed to have no oncological benefit from the resection (too much disease) or to be unfit for major surgery (too frail). The aim of this study was to assess the proportion and survival of…
Origen: Survival after non-resection of colorectal cancer: the argument for including non-operatives in consultant outcome reporting in the UK. – PubMed

Related Articles Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study. Digestion. 2016;93(3):229-33 Authors: Endlicher E, Schnoy E, Troppmann M, Rogler G, Messmann H, Klebl F, Gelbmann C, Kullmann F Abstract BACKGROUND: Since 2010, combination therapy with gemcitabine and cisplatin is the standard treatment for patients with biliary tract cancer (BTC) based on the ABC-02 trial. However, treatment after first-line progression is less clearly defined. We therefore retrospectively analyzed the efficacy of a 3-drug chemotherapy regimen in patients with advanced BTC. METHODS: Patients with advanced BTC treated with palliative chemotherapy between April 2000 and October 2005…
Origen: Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study. – PubMed

Related Articles Protocol for a phase III pragmatic stepped wedge cluster randomised controlled trial comparing the effectiveness and cost-effectiveness of screening and guidelines with, versus without, implementation strategies for improving pain in adults with cancer attending outpatient oncology and palliative care services: the Stop Cancer PAIN trial. BMC Health Serv Res. 2018 07 16;18(1):558 Authors: Luckett T, Phillips J, Agar M, Lam L, Davidson PM, McCaffrey N, Boyle F, Shaw T, Currow DC, Read A, Hosie A, Lovell M Abstract BACKGROUND: Pain is a common and distressing symptom in people with cancer, but is under-recognised and under-treated. Australian guidelines for…
Origen: Protocol for a phase III pragmatic stepped wedge cluster randomised controlled trial comparing the effectiveness and cost-effectiveness of screening and guidelines with, versus without, implementation strategies for improving pain in adults with cancer attending outpatient oncology and palliative care services: the Stop Cancer PAIN trial. – PubMed

Related Articles Samarium-153-(4-[((bis (phosphonomethyl)) carbamoyl) methyl]-7,10-bis (carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid: A novel agent for bone pain palliation therapy. J Cancer Res Ther. 2016 Jul-Sep;12(3):1117-1123 Authors: Yousefnia H, Enayati R, Hosntalab M, Zolghadri S, Bahrami-Samani A Abstract AIM: Various phosphonate ligands labeled with β–emitting radionuclides have shown good efficacy for bone pain palliation. In this study, a new agent for bone pain palliation has been developed. MATERIALS AND METHODS: Samarium-153-(4-[((bis(phosphonomethyl))carbamoyl)methyl]-7,10-bis (carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (153Sm-BPAMD) complex was prepared using BPAMD ligand and samarium-153 chloride. The effect of various parameters on the labeling yield of 153Sm-BPAMD including ligand concentration, pH, temperature, and reaction time…
Origen: Samarium-153-(4-[((bis (phosphonomethyl)) carbamoyl) methyl]-7,10-bis (carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid: A novel agent for bone pain palliation therapy. – PubMed

Related Articles Palliative Care is Associated with Reduced Aggressive End-of-Life Care in Patients with Gastrointestinal Cancer. Ann Surg Oncol. 2018 Jun;25(6):1478-1487 Authors: Merchant SJ, Brogly SB, Goldie C, Booth CM, Nanji S, Patel SV, Lajkosz K, Baxter NN Abstract BACKGROUND: We examined the delivery of physician palliative care (PC) services and its association with aggressive end-of-life care (EOLC) in patients with gastrointestinal (GI) cancer in Ontario, Canada. METHODS: All patients with primary cause of death from esophageal, gastric, colon, and anorectal cancer from January 2003 to December 2013 were identified. PC services within 2 years of death were classified: (1) any…
Origen: Palliative Care is Associated with Reduced Aggressive End-of-Life Care in Patients with Gastrointestinal Cancer. – PubMed